Kai Yuan

机构：Chinese PLA General Hospital, Changzhou No.2 People's Hospital, Changzhou Third People's Hospital · ORCID：0000-0001-7876-5490

发表论文 97 篇 · 总被引 1568 次 · h-index 22

代表论文

• Role of WTAP in Cancer: From Mechanisms to the Therapeutic Potential (2022 · Biomolecules · 被引 59)
• Corylifol A suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via attenuating ROS production and impairing mitochondrial function (2024 · Biomedicine & Pharmacotherapy · 被引 26)
• Isoimperatorin attenuates bone loss by inhibiting the binding of RANKL to RANK (2023 · Biochemical Pharmacology · 被引 22)
• MDFI is a novel biomarker for poor prognosis in LUAD (2022 · Frontiers in Oncology · 被引 16)
• Dehydromiltirone inhibits osteoclast differentiation in RAW264.7 and bone marrow macrophages by modulating MAPK and NF-κB activity (2022 · Frontiers in Pharmacology · 被引 16)
• Zuogui Pills alleviate iron overload-induced osteoporosis by attenuating ROS-mediated osteoblast apoptosis via the PI3K-AKT pathway and mitigating mitochondrial damage (2025 · Journal of Ethnopharmacology · 被引 12)